- Home
- CRVO vs CELU Comparison
CRVO vs CELU Comparison
Compare CRVO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- CELU
- Stock Information
- Founded
- CRVO 2001
- CELU 2016
- Country
- CRVO United States
- CELU United States
- Employees
- CRVO N/A
- CELU N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- CELU Health Care
- Exchange
- CRVO Nasdaq
- CELU Nasdaq
- Market Cap
- CRVO 67.4M
- CELU 64.3M
- IPO Year
- CRVO N/A
- CELU N/A
- Fundamental
- Price
- CRVO $10.51
- CELU $2.41
- Analyst Decision
- CRVO Strong Buy
- CELU Buy
- Analyst Count
- CRVO 6
- CELU 1
- Target Price
- CRVO $20.80
- CELU $6.00
- AVG Volume (30 Days)
- CRVO 119.1K
- CELU 112.4K
- Earning Date
- CRVO 08-08-2025
- CELU 08-29-2025
- Dividend Yield
- CRVO N/A
- CELU N/A
- EPS Growth
- CRVO N/A
- CELU N/A
- EPS
- CRVO N/A
- CELU N/A
- Revenue
- CRVO $7,776,968.00
- CELU $44,590,000.00
- Revenue This Year
- CRVO N/A
- CELU $23.29
- Revenue Next Year
- CRVO N/A
- CELU N/A
- P/E Ratio
- CRVO N/A
- CELU N/A
- Revenue Growth
- CRVO N/A
- CELU 4.45
- 52 Week Low
- CRVO $1.80
- CELU $1.00
- 52 Week High
- CRVO $20.63
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- CRVO 63.06
- CELU 35.71
- Support Level
- CRVO $9.61
- CELU $2.23
- Resistance Level
- CRVO $10.89
- CELU $4.00
- Average True Range (ATR)
- CRVO 0.67
- CELU 0.35
- MACD
- CRVO 0.04
- CELU -0.20
- Stochastic Oscillator
- CRVO 70.28
- CELU 8.87
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.